NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Cardiol Therapeutics Inc. (CRDL) Stock Analysis

Cardiol Therapeutics Inc. (CRDL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

CRDL

$2.20

+$0.04 (+1.85%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRDL with… →

CRDL Key Statistics

As of Sep 4, 2026

Trading

Open: $2.16
Previous Close: $2.16
Day's Range: 2.12–2.22
52-Week Range: 0.88–2.28
Volume: 1.10M
Beta: 0.61

Valuation

Market Cap: $257.01M
P/E Ratio: unprofitable
EPS (ttm): −0.25

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$33.82M
Profit margin: 0.00%
Shares Outstanding: 116.82M
1-Year Return: +98.20%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 991.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRDL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−5.51%−38.35%−15.14%−72.43%+65.29%+51.84%−25.47%+130.61%

20192020202120222023202420252026*

Year	Return
2026 (partial year)	+130.61%
2025	−25.47%
2024	+51.84%
2023	+65.29%
2022	−72.43%
2021	−15.14%
2020	−38.35%
2019	−5.51%

As of September 4, 2026.

CRDL Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$33.82M	—
2024	$0.00	−$36.68M	—
2023	$0.00	−$28.13M	—
2022	$0.00	−$30.93M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$34.32M	−$33.82M	—
2024	$0.00	—	−$40.28M	−$36.68M	—
2023	$0.00	—	−$29.79M	−$28.13M	—
2022	$0.00	—	−$41.34M	−$30.93M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRDL Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks

Metric	CRDL	Drug Manufacturers - Specialty & Generic median	vs median
Profit margin	0.00%	−3.14%	3.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cardiol Therapeutics Inc. (CRDL) at $257.01M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 18 employees.

The most recent close on file for CRDL is $2.20, dated September 4, 2026. That is +$0.04 (+1.85%) against the previous close. The 52-week range on file runs from $0.88 to $2.28. The latest close sits 150% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $33.82M. Profit margin runs at 0%. That is 3.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.25.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 0.61. Annualized volatility over the trailing 7 years is 86.43%. The trailing one-year price return is +98.20%. Across 5 years the annualized return works out at −10.45%.

Growth & Income

The record shows no dividend for CRDL.

So far in 2026 the price is +130.61%. Across the complete calendar years on file, 2023 returned +65.29% and 2022 returned −72.43%. Of the 7 complete calendar years on file, 2 finished higher.

Peer Comparison

Cardiol Therapeutics Inc. (CRDL) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cardiol Therapeutics Inc.	CRDL	$257.01M	—
Takeda Pharmaceutical Company Limited	TAK	$58.92B	—
Teva Pharmaceutical Industries Limited	TEVA	$42.37B	60.6
Haleon plc	HLN	$42.22B	20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Cardiol Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

TEVA

Teva Pharmaceutical Industries Limited

$42.37B

HLN

Haleon plc

$42.22B

ZTS

Zoetis Inc.

$31.33B

UTHR

United Therapeutics Corporation

$20.91B

VTRS

Viatris Inc.

$19.39B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Visit website →